Literature DB >> 2222131

Controlled comparisons of clomipramine and fluoxetine in the treatment of obsessive-compulsive disorder. Behavioral and biological results.

T A Pigott1, M T Pato, S E Bernstein, G N Grover, J L Hill, T J Tolliver, D L Murphy.   

Abstract

Treatment with fluoxetine hydrochloride was compared with treatment with clomipramine hydrochloride in two groups of patients with obsessive-compulsive disorder using two different experimental designs. In the first group of 11 patients with obsessive-compulsive disorder studied using a randomized, double-blind, crossover design, treatment with fluoxetine for 10 weeks was found to produce therapeutic effects similar to treatment with clomipramine for 10 weeks. There were significantly fewer total side effects reported during fluoxetine than clomipramine treatment. Drug tapering and placebo substitution in the 4-week crossover interval phase led to substantial relapses in obsessive-compulsive disorder symptoms and depression. Furthermore, responses to the second drug took as long to occur as responses to the first drug, although both drugs are thought to act by a common mechanism, serotonin uptake inhibition. A second group of 21 patients with obsessive-compulsive disorder that had been previously stabilized on clomipramine treatment with at least partial benefit were crossed over to fluoxetine treatment in a double-blind fashion. After 10 weeks of fluoxetine administration, most patients manifested behavioral rating scores of obsessive-compulsive disorder and depressive symptoms that were comparable with precrossover ratings completed during clomipramine treatment. A significant exacerbation in obsessive-compulsive disorder and depression ratings as well as a similar lag in therapeutic efficacy were also noted in this second cohort of patients with obsessive-compulsive disorder. Platelet 5-HT concentrations were reduced 95% during both clomipramine and fluoxetine treatment periods. These results suggest that fluoxetine may represent a viable alternative to clomipramine in the treatment of obsessive-compulsive disorder, although further studies with larger sample sizes are needed.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2222131     DOI: 10.1001/archpsyc.1990.01810220042005

Source DB:  PubMed          Journal:  Arch Gen Psychiatry        ISSN: 0003-990X


  17 in total

Review 1.  Clinical pharmacology and therapeutics.

Authors:  R C Horton; M J Kendall
Journal:  Postgrad Med J       Date:  1991-12       Impact factor: 2.401

Review 2.  A risk-benefit assessment of drugs used in the management of obsessive-compulsive disorder.

Authors:  L L Carpenter; C J McDougle; C N Epperson; L H Price
Journal:  Drug Saf       Date:  1996-08       Impact factor: 5.606

Review 3.  How the serotonin story is being rewritten by new gene-based discoveries principally related to SLC6A4, the serotonin transporter gene, which functions to influence all cellular serotonin systems.

Authors:  Dennis L Murphy; Meredith A Fox; Kiara R Timpano; Pablo R Moya; Renee Ren-Patterson; Anne M Andrews; Andrew Holmes; Klaus-Peter Lesch; Jens R Wendland
Journal:  Neuropharmacology       Date:  2008-09-11       Impact factor: 5.250

Review 4.  Changes in clinical trials methodology over time: a systematic review of six decades of research in psychopharmacology.

Authors:  André R Brunoni; Laura Tadini; Felipe Fregni
Journal:  PLoS One       Date:  2010-03-03       Impact factor: 3.240

5.  Obsessive compulsive neurosis : clomipramine, prolactin and therapeutic response.

Authors:  J Ananth; A Kaur; R Poland; M Wohl
Journal:  Indian J Psychiatry       Date:  1997-04       Impact factor: 1.759

6.  Effects of chronic fluoxetine treatment on serotonin 1B receptor-induced deficits in delayed alternation.

Authors:  Nancy S Woehrle; Stephanie J Klenotich; Naseem Jamnia; Emily V Ho; Stephanie C Dulawa
Journal:  Psychopharmacology (Berl)       Date:  2013-02-03       Impact factor: 4.530

7.  Defining cognitive-behavior therapy response and remission in pediatric OCD: a signal detection analysis of the Children's Yale-Brown Obsessive Compulsive Scale.

Authors:  Gudmundur Skarphedinsson; Alessandro S De Nadai; Eric A Storch; Adam B Lewin; Tord Ivarsson
Journal:  Eur Child Adolesc Psychiatry       Date:  2016-05-21       Impact factor: 4.785

Review 8.  Current concepts in the pharmacological treatment of obsessive-compulsive disorder.

Authors:  J Zohar; R C Zohar-Kadouch; S Kindler
Journal:  Drugs       Date:  1992-02       Impact factor: 9.546

9.  Monoamine activity reflected in urine of young patients with obsessive compulsive disorder, psychosis with and without reality distortion and healthy subjects: an explorative analysis.

Authors:  R D Oades; B Röpcke; C Eggers
Journal:  J Neural Transm Gen Sect       Date:  1994

Review 10.  Recent advances in geriatric psychopharmacology.

Authors:  C A Naranjo; N Herrmann; N Mittmann; K E Bremner
Journal:  Drugs Aging       Date:  1995-09       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.